Related Experiment Video
Updated: Mar 6, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
The Effect of Molecular Diagnostics on the Treatment of Glioma
Nancy Ann Oberheim Bush1, Nicholas Butowski2
1Division of Neuro-Oncology, Department of Neurological Surgery, University of California, 400 Parnassus Ave, A808, San Francisco, CA, USA.
Purpose Of Review:
This review summarizes the use of molecular diagnostics in glioma and its effect on the development of novel therapeutics and management decisions.
Recent Findings:
Genomic and proteomic profiling of brain tumors has provided significant expansion of our understanding of oncogenesis, characterization, and prognostication of brain tumors. Molecular markers such as MGMT, EGFR, IDH, 1p19q, ATRX, TERT, FGFR-TACC, and BRAF are now being used to classify brain tumors as well as influence management decisions. Several of these markers are also being used as therapeutic targets. We review the use of several molecular diagnostics in gliomas and discuss their impact on drug development and clinical trial design. In the future, molecular characterization based on a specific genomic, proteomic as well as transcriptomes for bioformatics analysis will provide clinicians the ability to rationally select drugs with actionable targets for each patient.
